Aug. 6, 2009  15  US 2009/0197849 Al  zankiren hydrochloride, zofenoprilat arginine; pharmaceuti› cally acceptable derivatives thereof, and combinations  thereof.  [0155]  Of particular interest are a-adrenergic antagonists  such as doxazosin, phenoxybenzamine, prazosin, and tera› zosin; angiotensin converting enzyme inhibitors such as  benazepril, benazeprilat, enalapril, enelaprilat, fosinopril,  fosinoprilat, lisinopril, perindopril, perindoprilat, quinapril,  quinaprilat, ramipril, and ramiprilat; ~-blockers such as  carvedilol, nadolol, and timolol; and calcium channel block› ers such as amlodipine, felodipine, isradipine, nicardipine,  nifedipine, and nimodipine; as well as pharmaceutically  acceptable derivatives thereof.  [0156]  Derivatives of the aforementioned compounds, such  as pharmaceutically acceptable salts and esters are also of  particular interest, for example, doxazosin mesylate, enala› pril maleate, fosinopril sodium, losartan potassium, prazosin  HCl, terazosin HCl, as well as those included in the list above.  [0157]  The methods and compositions of the invention are  expected to provide an enhanced flux of antihypertensive  agents of at least about 30-fold, preferably at least about  50-fold, and more preferably about 63-fold, as compared to  the flux observed in the absence of the basic enhancers  described herein.  [0158]  0. Antiparkinsonism Drugs  [0159]  Suitable antiparkinsonism drugs that may be admin› istered using the methods, compositions and systems of the  invention include, but are not limited to: anticholinergics such  as amantadine, benztropine, beperiden, cycrimine, procycli› dine, and trihexyphenidyl; antidyskinetics such as selegiline;  cabergoline; COMT inhibitors such as entacapone and tolca› pone, both of which are administered with levodopa/carbi› dopa; diphenhydramine; dopamine receptor agonists such as  bromocriptine, levodopa/carbidopa, metoclopramide, per› golide, pramipexole and ropinirole; as well as other com› pounds such as diphenhydramine and hyoscyamine.  [0160]  Preferred antiparkinsonism drugs include benz› tropine, biperiden, bromocriptine, carbidopa, levodopa,  diphenhydramine, hyoscyamine, pergolide, pramipexole,  ropinirole, selegiline, and trihexyphenidyl.  [0161]  Derivatives of these compounds, such as pharma› ceutically acceptable salts and esters are also of particular  interest, for example, amantadine HCl, benztropine mesylate,  biperiden HCl, bromocriptine mesylate, carbidopa, levodopa,  diphenhydramine HCl, hyoscyamine sulfate, pergolide  mesylate, pramipexole dihydrochloride, ropinirole HCl, sel› egiline HCl, and trihexyphenidyl HCI.  [0162]  P. Antipsychotic Agents  [0163]  Suitable antipsychotics agents that may be admin› istered using the methods, compositions and systems of the  invention include, but are not limited to: acetophenazine  maleate, alentemol hydrobromide, alpertine, azaperone,  batelapine maleate, benperidol, benzindopyrine hydrochlo› ride, brofbxine, bromperidol and bromperidol decanoate,  buspirone, butaclamol hydrochloride, butaperazine and  butaperazine maleate, carphenazine maleate, carvotroline  hydrochloride, chlorpromazine and chlorpromazine hydro› chloride, chlorprothixene, cinperene, cintriamide, clomacran  phosphate, clopenthixol, clopimozide, clopipazan mesylate,  cloroperone hydrochloride, clothiapine, clothixamide male› ate, clozapine, cyclophenazine hydrochloride, droperidol,  etazolate hydrochloride, fenimide, flucindole, flumezapine,  fluphenazine decanoate and fluphenazine enanthate and  fluphenazine  hydrochloride,  fluspiperone,  fluspirilene,  flutroline, gevotroline hydrochloride, halopemide, haloperi› dol and haloperidol decanoate, iloperidone, imidoline hydro› chloride,  lenperone,  loxapine,  mazapertine  succinate,  mesoridazine and mesoridazine besylate, metiapine, milen› perone, milipertine, molindone and molindone hydrochlo› ride, naranol hydrochloride, neflumozidehydrochloride, oca› peridone, olanzapine, oxiperomide, penfluridol, pentiapine  maleate, perphenazine, pimozide, pinoxepin hydrochloride,  pipamperone, piperacetazine, pipotiazine palniitate, piquin› done hydrochloride, prochlorperazine and prochlorperazine  edisylate and prochlorperazine maleate, promazine hydro› chloride, quetiapine and quetiapine fumarate, remoxipride  and remoxipride hydrochloride, rimcazole hydrochloride,  risperidone, seperidol hydrochloride, sertindole, setoperone,  spiperone, thioridazine and thioridazine hydrochloride, thio› thixene and thiothixene hydrochloride, tioperidone hydro› chloride, tiospirone hydrochloride, trifluoroperazine and tri› fluoperazine hydrochloride, trifluperidol, triflupromazine  and triflupromazine hydrochloride, ziprasidone and ziprasi› done hydrochloride.  [0164]  Derivatives of these compounds, such as pharma› ceutically acceptable salts and esters are also of particular  interest, for example, trifluoperazine HCl, as well as those  included in the list above.  [0165]  Preferred antipsychotics are atypical antipsychotic  agents (i.e., drugs that act on different neurotransmitters than  the conventions antipsychotic agents) such as clozapine,  olanzapine, quetiapine fumarate, and risperidone; conven› tional  antipsychotic  agents  such  as  chlorpromazine,  fluphenazine, haloperidol, loxapine, mesoridazine, per› phenazine, pimozide, prochlorperazine (and other phenothi› azines), thiothixene and trifluoroperazine; and related drugs  such as buspirone.  [0166]  Most preferred antipsychotic agents include bus› pirone, olanzapine, pimozide, prochlorperazine, risperidone  and trifluoroperazine.  [0167]  The methods and compositions of the invention are  expected to provide an enhanced flux of antipsychotic agents  of at least about 15-fold, preferably at least about 35-fold, as  compared to the flux observed in the absence of the basic  enhancers described herein.  [0168]  Q. Bone Density Regulators  [0169]  Suitable bone density regulators that may be admin› istered using the methods, compositions and systems of the  invention include, but are not limited to: alendronate, calci› tonin, etidronate, pamidronate, raloxifene, risedronate, and  tiludronate. Derivatives of these compounds, such as pharma› ceutically acceptable salts and esters are also of particular  interest, for example, alendronate sodium, etidronate sodium  and etidronate disodium, pamidronate disodium, raloxifene  HCl, risedronate sodium, and tiludronate sodium. Preferred  bone density regulators include alendronate, etidronate, ral› oxifene, and risedronate, tiludronate, and pharmaceutically  acceptable derivatives thereof.  [0170]  The methods and compositions of the invention are  expected to provide an enhanced flux of bone density regu› lators of at least about 2-fold, preferably at least about 3-fold,  as compared to the flux observed in the absence of the basic  enhancers described herein.  [0171]  R. Analgesic Agents  [0172]  Suitable analgesic agents that may be administered  using the methods, compositions and systems of the invention  include, but are not limited to: capsaicin, indomethacin, and  centrally acting analgesics such as clonidine and tramadol. Of 